Y-mAbs Therapeutics (NASDAQ:YMAB) Upgraded by Wall Street Zen to “Hold” Rating

Y-mAbs Therapeutics (NASDAQ:YMAB) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Several other analysts also recently commented on YMAB. Canaccord Genuity Group downgraded shares of Y-mAbs Therapeutics from a “strong-buy” rating to a “hold” rating and decreased their price objective for the stock from $26.00 to $8.60 in a report on Tuesday, August 5th. Wedbush cut shares of Y-mAbs Therapeutics from a “strong-buy” rating to a “hold” rating and set a $8.60 price target on the stock. in a report on Tuesday, August 5th. Morgan Stanley set a $8.60 target price on Y-mAbs Therapeutics in a research report on Tuesday, August 5th. HC Wainwright reiterated a “neutral” rating and set a $8.60 target price (down from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th. Finally, Oppenheimer lowered Y-mAbs Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 5th. Eight equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $9.62.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock opened at $8.61 on Friday. The firm’s fifty day moving average price is $7.27 and its two-hundred day moving average price is $5.49. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11. The firm has a market capitalization of $391.24 million, a P/E ratio of -17.22 and a beta of 0.54.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.20. The firm had revenue of $19.52 million during the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. As a group, equities research analysts forecast that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC raised its position in shares of Y-mAbs Therapeutics by 223.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 155,522 shares of the company’s stock worth $689,000 after acquiring an additional 107,511 shares in the last quarter. Bank of America Corp DE increased its position in Y-mAbs Therapeutics by 59.5% during the fourth quarter. Bank of America Corp DE now owns 127,159 shares of the company’s stock worth $996,000 after buying an additional 47,439 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Y-mAbs Therapeutics by 107.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company’s stock valued at $119,000 after purchasing an additional 13,890 shares during the last quarter. Nuveen LLC purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at approximately $498,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Y-mAbs Therapeutics by 58.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company’s stock valued at $1,052,000 after buying an additional 87,830 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.